（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]

证券日报网讯陇神戎发（300534）7月31日在互动平台回答投资者提问时表示，公司坚持以市场为导 向，强化内外部协同创新，深耕主打品种二次开发的同时，积极开展新产品的研发工作。 ...

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

Company Developments - Company announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two Clinical Trial Supplement Approval Notices from the National Medical Products Administration on July 30 [1] - The approval allows for the continuation of clinical trials for the drug Brupiprazole oral film, specifically adding 0.5mg and 1mg specifications for the treatment of schizophrenia [1] - The company reported a revenue of 1.039 billion yuan for 2024, a decrease of 3.79% year-on-year, and a net profit attributable to shareholders of 25.8046 million yuan, down 58.14% year-on-year [2] Industry Insights - The company is optimistic about the prospects in the health sector and is actively developing health products, including Huangqi Danggui capsules and plant-based beverages [3] - Recent government policies have been introduced to support the innovation and development of traditional Chinese medicine, which is expected to enhance the quality and market demand for traditional Chinese medicine products [3] - The aging population is increasing the demand for disease prevention and chronic disease management, which is expected to further expand the market for traditional Chinese medicine products [3]

Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two approval notices from the National Medical Products Administration for clinical trial supplement applications on July 30, 2025 [1] Group 1 - The clinical trial for the drug Bupropion oral dissolving film has been approved to add specifications of 0.5mg and 1mg [1] - Bupropion oral dissolving film is intended for the treatment of schizophrenia [1] - The supplement application primarily aims to increase the relevant specifications for the clinical trial, which will continue to be conducted [1] Group 2 - According to China's drug registration laws and regulations, after obtaining the clinical trial approval notice, the drug must undergo clinical trials and receive review and approval from the National Medical Products Administration before it can be produced and marketed [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trials of Brivaracetam, indicating ongoing development in the treatment of schizophrenia [1] - Clinical trials will continue following the approval, and the drug must undergo further evaluation and approval by the National Medical Products Administration before it can be manufactured and marketed [1]

Core Viewpoint - The company, Longshen Rongfa, announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film, which is intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of two new specifications: 0.5mg and 1mg [1] - The supplementary application was accepted on May 20 and meets the requirements for drug registration [1] - The clinical trials for Brivaracetam oral film can continue as per the approved content [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trial of Brivaracetam oral film [1] - The clinical trial work will continue following the approval, as per the requirements of China's drug registration laws and regulations [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-051 甘肃陇神戎发药业股份有限公司 关于控股子公司获得药物临床试验补充申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）于 2025 年 7 月 30 日收到国家药品 监督管理局核准签发的 2 份《药物临床试验补充申请批准通知书》，现将相关情 况公告如下： 一、《药物临床试验补充申请批准通知书》的主要内容 药物名称：布瑞哌唑口溶膜 受理号：CXHB2500137、CXHB2500138 通知书编号：2025LB00513、2025LB00514 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 5 月 20 日受理的布瑞哌唑口溶膜为已获得批准的药物临床试验申请（受理号：C X H L 2 5 0 0 0 8 2，通知书编号 2025LP00911）的补充申请，此次药物临床试验补充 申请符合药品注册的有关要求，同意本品按照批准内容继续开展临床试验。批准 ...